Ulrich Herrlinger

List of Publications by Year
in descending order

148 papers	8,839 citations	44069 48 h-index	45317 90 g-index
150 all docs	150 docs citations	150 times ranked	9484 citing authors

#	Article	IF	Citations
1	Tumor-associated epilepsy in patients with brain metastases: necrosis-to-tumor ratio forecasts postoperative seizure freedom. Neurosurgical Review, 2022, 45, 545-551.	2.4	2
2	Perioperative red blood cell transfusion is associated with poor functional outcome and overall survival in patients with newly diagnosed glioblastoma. Neurosurgical Review, 2022, 45, 1327-1333.	2.4	3
3	Phase I/II trial of meclofenamate in progressive MGMT-methylated glioblastoma under temozolomide second-line therapyâ€"the MecMeth/NOA-24 trial. Trials, 2022, 23, 57.	1.6	10
4	Proliferative Potential, and Inflammatory Tumor Microenvironment in Meningioma Correlate with Neurological Function at Presentation and Anatomical Locationâ€"From Convexity to Skull Base and Spine. Cancers, 2022, 14, 1033.	3.7	9
5	Sex-Dependent Analysis of Temozolomide-Induced Myelosuppression and Effects on Survival in a Large Real-life Cohort of Patients With Glioma. Neurology, 2022, 98, .	1.1	2
6	Inflammatory Tumor Microenvironment in Cranial Meningiomas: Clinical Implications and Intraindividual Reproducibility. Diagnostics, 2022, 12, 853.	2.6	3
7	Benchmarking Safety Indicators of Surgical Treatment of Brain Metastases Combined with Intraoperative Radiotherapy: Results of Prospective Observational Study with Comparative Matched-Pair Analysis. Cancers, 2022, 14, 1515.	3.7	11
8	Impact of Levetiracetam Treatment on 5-Aminolevulinic Acid Fluorescence Expression in IDH1 Wild-Type Glioblastoma. Cancers, 2022, 14, 2134.	3.7	1
9	Disconnecting multicellular networks in brain tumours. Nature Reviews Cancer, 2022, 22, 481-491.	28.4	44
10	Radiotherapy and olaptesed pegol (NOX-A12) in partially resected or biopsy-only MGMT-unmethylated glioblastoma: Interim data from the German multicenter phase 1/2 GLORIA trial.. Journal of Clinical Oncology, 2022, 40, 2050-2050.	1.6	1
11	Early treatment response assessment using ¹⁸F-FET PET compared to contrast-enhanced MRI in glioma patients following adjuvant temozolomide chemotherapy. Journal of Nuclear Medicine, 2021, 62, jnumed.120.254243.	5.0	25
12	Impact of initial midline shift in glioblastoma on survival. Neurosurgical Review, 2021, 44, 1401-1409.	2.4	11
13	<scp>MGMT</scp> promoter methylation analysis for allocating combined <scp>CCNU</scp>/<scp>TMZ</scp> chemotherapy: Lessons learned from the <scp>CeTeG</scp>/<scp>NOA</scp>â€09 trial. International Journal of Cancer, 2021, 148, 1695-1707.	5.1	11
14	Machine learning-based differentiation between multiple sclerosis and glioma WHO IIÂ°-IVÂ° using O-(2-[18F] fluoroethyl)-L-tyrosine positron emission tomography. Journal of Neuro-Oncology, 2021, 152, 325-332.	2.9	11
15	Seizure outcome in temporal glioblastoma surgery: lobectomy as a supratotal resection regime outclasses conventional gross-total resection. Journal of Neuro-Oncology, 2021, 152, 339-346.	2.9	12
16	Inhibition of Intercellular Cytosolic Traffic via Gap Junctions Reinforces Lomustine-Induced Toxicity in Glioblastoma Independent of MGMT Promoter Methylation Status. Pharmaceuticals, 2021, 14, 195.	3.8	7
17	Prognostic Value of Preoperative Inflammatory Markers in Melanoma Patients with Brain Metastases. Journal of Clinical Medicine, 2021, 10, 634.	2.4	12
18	The Impact of Prolonged Mechanical Ventilation on Overall Survival in Patients With Surgically Treated Brain Metastases. Frontiers in Oncology, 2021, 11, 658949.	2.8	10

#	Article	IF	Citations
19	Chemotherapy for adult patients with spinal cord gliomas. Neuro-Oncology Practice, 2021, 8, 475-484.	1.6	1
20	Baseline Serum C-Reactive Protein and Plasma Fibrinogen-Based Score in the Prediction of Survival in Glioblastoma. Frontiers in Oncology, 2021, 11, 653614.	2.8	14
21	Meclofenamate causes loss of cellular tethering and decoupling of functional networks in glioblastoma. Neuro-Oncology, 2021, 23, 1885-1897.	1.2	23
22	Prognostic factors in leptomeningeal metastases. Neuro-Oncology, 2021, 23, 1208-1209.	1.2	0
23	Diagnosis of Pseudoprogression Following Lomustineâ€“Temozolomide Chemoradiation in Newly Diagnosed Glioblastoma Patients Using FET-PET. Clinical Cancer Research, 2021, 27, 3704-3713.	7.0	19
24	No evidence to support the impact of migration background on treatment response rates and cancer survival: a retrospective matched-pair analysis in Germany. BMC Cancer, 2021, 21, 526.	2.6	3
25	The value of bone marrow biopsy for staging of patients with primary CNS lymphoma. Neuro-Oncology, 2021, 23, 2076-2084.	1.2	9
26	Implementation, relevance, and virtual adaptation of neuro-oncological tumor boards during the COVID-19 pandemic: a nationwide provider survey. Journal of Neuro-Oncology, 2021, 153, 479-485.	2.9	20
27	Mean Platelet Volume/Platelet Count Ratio and Risk of Progression in Glioblastoma. Frontiers in Oncology, 2021, 11, 695316.	2.8	6
28	Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC) Tj ETQq0 0 0 rgBT /Overlock 10 Oncology, The, 2021, 22, 813-823.	10.7	132
29	Outcome of Elderly Patients With Surgically Treated Brain Metastases. Frontiers in Oncology, 2021, 11, 713965.	2.8	14
30	FORGE: A Novel Scoring System to Predict the MIB-1 Labeling Index in Intracranial Meningiomas. Cancers, 2021, 13, 3643.	3.7	10
31	Combined Assessment of Preoperative Frailty and Sarcopenia Allows the Prediction of Overall Survival in Patients with Lung Cancer (NSCLC) and Surgically Treated Brain Metastasis. Cancers, 2021, 13, 3353.	3.7	18
32	Extracellular Vesicle Separation Techniques Impact Results from Human Blood Samples: Considerations for Diagnostic Applications. International Journal of Molecular Sciences, 2021, 22, 9211.	4.1	13
33	Red blood cell distribution width to platelet ratio substantiates preoperative survival prediction in patients with newly-diagnosed glioblastoma. Journal of Neuro-Oncology, 2021, 154, 229-235.	2.9	8
34	Preoperative Metastatic Brain Tumor-Associated Intracerebral Hemorrhage Is Associated With Dismal Prognosis. Frontiers in Oncology, 2021, 11, 699860.	2.8	11
35	The Surgical Management of Brain Metastases in Non-Small Cell Lung Cancer (NSCLC): Identification of the Early Laboratory and Clinical Determinants of Survival. Journal of Clinical Medicine, 2021, 10, 4013.	2.4	1
36	Prognostic validation and clinical implications of the EANO ESMO classification of leptomeningeal metastasis from solid tumors. Neuro-Oncology, 2021, 23, 1100-1112.	1.2	59

#	Article	IF	Citations
37	ACKT: A Proposal for a Novel Score to Predict Prolonged Mechanical Ventilation after Surgical Treatment of Meningioma in Geriatric Patients. Cancers, 2021, 13, 98.	3.7	3
38	Dosimetric Comparison of Upfront Boosting With Stereotactic Radiosurgery Versus Intraoperative Radiotherapy for Glioblastoma. Frontiers in Oncology, 2021, 11, 759873.	2.8	7
39	BIOM-08. DNA METHYLATION-BASED SUBGROUPING PREDICTS SURVIVAL BENEFIT FROM LOMUSTINE/TEMOZOLOMID COMBINATION THERAPY IN MGMT PROMOTOR-METHYLATED GLIOBLASTOMA. Neuro-Oncology, 2021, 23, vi11-vi11.	1.2	0
40	BIOM-24. PROTEIN SURFACE SIGNATURE ON SERUM EXTRACELLULAR VESICLES FOR NON-INVASIVE DETECTION OF TUMOR PROGRESSION IN GLIOBLASTOMA PATIENTS. Neuro-Oncology, 2021, 23, vi15-vi16.	1.2	0
41	Chasing aÂrarity: aÂretrospective single-center evaluation of prognostic factors in primary gliosarcoma. Strahlentherapie Und Onkologie, 2021, , 1.	2.0	2
42	The Colony Stimulating Factor-1 Receptor (CSF-1R)-Mediated Regulation of Microglia/Macrophages as a Target for Neurological Disorders (Glioma, Stroke). Frontiers in Immunology, 2021, 12, 787307.	4.8	21
43	Tumour Treating Fields (TTFields) in combination with lomustine and temozolomide in patients with newly diagnosed glioblastoma. Journal of Cancer Research and Clinical Oncology, 2020, 146, 787-792.	2.5	26
44	Twenty-year follow-up of a pilot/phase II trial on the Bonn protocol for primary CNS lymphoma. Neurology, 2020, 95, e3138-e3144.	1.1	18
45	Analysis of Serum miRNA in Glioblastoma Patients: CD44-Based Enrichment of Extracellular Vesicles Enhances Specificity for the Prognostic Signature. International Journal of Molecular Sciences, 2020, 21, 7211.	4.1	17
46	Safety metric profiling in surgery for temporal glioblastoma: lobectomy as a supra-total resection regime preserves perioperative standard quality rates. Journal of Neuro-Oncology, 2020, 149, 455-461.	2.9	16
47	A Preliminary Study on Machine Learning-Based Evaluation of Static and Dynamic FET-PET for the Detection of Pseudoprogression in Patients with IDH-Wildtype Glioblastoma. Cancers, 2020, 12, 3080.	3.7	25
48	Outcome of Tumor-Associated Proptosis in Patients With Spheno-Orbital Meningioma: Single-Center Experience and Systematic Review of the Literature. Frontiers in Oncology, 2020, 10, 574074.	2.8	9
49	News on the horizon in glioblastoma therapy. ESMO Open, 2020, 5, e000601.	4.5	1
50	Development of a gene expressionâ€“based prognostic signature for IDH wild-type glioblastoma. Neuro-Oncology, 2020, 22, 1742-1756.	1.2	18
51	Higher number of multidisciplinary tumor board meetings per case leads to improved clinical outcome. BMC Cancer, 2020, 20, 355.	2.6	33
52	Postoperative Prolonged Mechanical Ventilation in Patients With Newly Diagnosed Glioblastomaâ€”An Unrecognized Prognostic Factor. Frontiers in Oncology, 2020, 10, 607557.	2.8	9
53	Comorbidity Burden and Presence of Multiple Intracranial Lesions Are Associated with Adverse Events after Surgical Treatment of Patients with Brain Metastases. Cancers, 2020, 12, 3209.	3.7	21
54	Neurocognitive functioning and health-related quality of life in adult medulloblastoma patients: long-term outcomes of the NOA-07 study. Journal of Neuro-Oncology, 2020, 148, 117-130.	2.9	12

#	Article	IF	Citations
55	Treatment of metastasized melanoma with combined checkpoint inhibition in a patient with highly active multiple sclerosis. Journal of Dermatology, 2020, 47, e184-e185.	1.2	0
56	Superiority of temozolomide over radiotherapy for elderly patients with RTK II methylation class, MGMT promoter methylated malignant astrocytoma. Neuro-Oncology, 2020, 22, 1162-1172.	1.2	42
57	Effect of early palliative care for patients with glioblastoma (EPCOG): a randomised phase III clinical trial protocol. BMJ Open, 2020, 10, e034378.	1.9	26
58	Newly diagnosed glioblastoma in geriatric (65â€‰+) patients: impact of patients frailty, comorbidity burden and obesity on overall survival. Journal of Neuro-Oncology, 2020, 149, 421-427.	2.9	20
59	Neuroonkologie. , 2020, , 257-271.		0
60	NIMG-26. DIAGNOSIS OF PSEUDOPROGRESSION FOLLOWING RADIOTHERAPY PLUS LOMUSTINE-TEMOZOLOMIDE CHEMOTHERAPY IN NEWLY DIAGNOSED GLIOBLASTOMA PATIENTS USING FET PET. Neuro-Oncology, 2020, 22, ii152-ii153.	1.2	0
61	NIMG-14. MACHINE LEARNING-BASED EVALUATION OF STATIC AND DYNAMIC FET-PET FOR THE DETECTION OF PSEUDOPROGRESSION IN PATIENTS WITH IDH-WILDTYPE GLIOBLASTOMA. Neuro-Oncology, 2020, 22, ii149-ii150.	1.2	0
62	BIOM-40. ANALYSIS OF SERUM MIRNA IN GLIOBLASTOMA PATIENTS: TARGETED ENRICHMENT OF EXTRACELLULAR VESICLES ENHANCES SPECIFICITY FOR PROGNOSTIC SIGNATURE. Neuro-Oncology, 2020, 22, ii10-ii10.	1.2	0
63	Longitudinal, leakage corrected and uncorrected rCBV during the first-line treatment of glioblastoma: a prospective study. Journal of Neuro-Oncology, 2019, 144, 409-417.	2.9	7
64	PDGRFB mutationâ€associated myofibromatosis: Response to targeted therapy with imatinib. American Journal of Medical Genetics, Part A, 2019, 179, 1895-1897.	1.2	14
65	Tumor Vessel Normalization, Immunostimulatory Reprogramming, and Improved Survival in Glioblastoma with Combined Inhibition of PD-1, Angiopoietin-2, and VEGF. Cancer Immunology Research, 2019, 7, 1910-1927.	3.4	74
66	Corticosteroid-responsive aseptic meningitis during regorafenib treatment. Neuro-Oncology Practice, 2019, 6, 508-509.	1.6	2
67	Surgery for temporal glioblastoma: lobectomy outranks oncosurgical-based gross-total resection. Journal of Neuro-Oncology, 2019, 145, 143-150.	2.9	23
68	Health-related quality of life and neurocognitive functioning with lomustineâ€“temozolomide versus temozolomide in patients with newly diagnosed, MGMT-methylated glioblastoma (CeTeG/NOA-09): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncology, The, 2019, 20, 1444-1453.	10.7	29
69	The added value of health-related quality of life as a prognostic indicator of overall survival and progression-free survival in glioma patients: a meta-analysis based on individual patient data from randomised controlled trials. European Journal of Cancer, 2019, 116, 190-198.	2.8	22
70	Inhibition of Gap Junctions Sensitizes Primary Glioblastoma Cells for Temozolomide. Cancers, 2019, 11, 858.	3.7	20
71	Regorafenib in advanced high-grade glioma: a retrospective bicentric analysis. Neuro-Oncology, 2019, 21, 954-955.	1.2	15
72	Longitudinal heterogeneity in glioblastoma: moving targets in recurrent versus primary tumors. Journal of Translational Medicine, 2019, 17, 96.	4.4	54

#	Article	IF	Citations
73	Targeting the Post-Irradiation Tumor Microenvironment in Glioblastoma via Inhibition of CXCL12. Cancers, 2019, 11, 272.	3.7	15
74	Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOAâ€“09): a randomised, open-label, phase 3 trial. Lancet, The, 2019, 393, 678-688.	13.7	384
75	A matched-pair analysis on survival and response rates between German and non-German cancer patients treated at a Comprehensive Cancer Center. BMC Cancer, 2019, 19, 1024.	2.6	5
76	Quality of life in the GLARIUS trial randomizing bevacizumab/irinotecan versus temozolomide in newly diagnosed, MGMT-nonmethylated glioblastoma. Neuro-Oncology, 2018, 20, 975-985.	1.2	11
77	Multicenter pilot study of radiochemotherapy as first-line treatment for adults with medulloblastoma (NOA-07). Neuro-Oncology, 2018, 20, 400-410.	1.2	56
78	QOLP-29. SYMPTOM CLUSTERS IN NEWLY DIAGNOSED GLIOMA PATIENTS: WHICH CLUSTERS ARE ASSOCIATED WITH FUNCTIONING AND GLOBAL HEALTH STATUS?. Neuro-Oncology, 2018, 20, vi221-vi221.	1.2	0
79	ACTR-64. OBJECTIVE RESPONSES TO CHEMOTHERAPY IN RECURRENT GLIOMA DO NOT PREDICT BETTER SURVIVAL: A PROSPECTIVE ANALYSIS FROM THE GERMAN GLIOMA NETWORK. Neuro-Oncology, 2018, 20, vi26-vi26.	1.2	0
80	NIMG-79. EARLY TREATMENT RESPONSE ASSESSMENT USING O-(2-18F-FLUOROETHYL)-L-TYROSINE (FET) PET COMPARED TO MRI IN MALIGNANT GLIOMAS TREATED WITH ADJUVANT TEMOZOLOMIDE CHEMOTHERAPY. Neuro-Oncology, 2018, 20, vi193-vi193.	1.2	2
81	Recurrent pseudoprogression in isocitrate dehydrogenase 1 mutant glioblastoma. Journal of Clinical Neuroscience, 2018, 53, 255-258.	1.5	1
82	DNA methylation-based classification of ependymomas in adulthood: implications for diagnosis and treatment. Neuro-Oncology, 2018, 20, 1616-1624.	1.2	65
83	Early whole brain radiotherapy in primary CNS lymphoma: negative impact on quality of life in the randomized G-PCNSL-SG1 trial. Journal of Cancer Research and Clinical Oncology, 2017, 143, 1815-1821.	2.5	57
84	Quantitative T1â€•mapping detects cloudyâ€•enhancing tumor compartments predicting outcome of patients with glioblastoma. Cancer Medicine, 2017, 6, 89-99.	2.8	44
85	Limited role for extended maintenance temozolomide for newly diagnosed glioblastoma. Neurology, 2017, 88, 1422-1430.	1.1	54
86	Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study. Lancet, The, 2017, 390, 1645-1653.	13.7	307
87	Current status and perspectives of interventional clinical trials for glioblastoma â€“ analysis of ClinicalTrials.gov. Radiation Oncology, 2017, 12, 1.	2.7	87
88	ACTR-58. PHASE III TRIAL OF CCNU/TEMOZOLOMIDE (TMZ) COMBINATION THERAPY VS. STANDARD TMZ THERAPY FOR NEWLY DIAGNOSED MGMT-METHYLATED GLIOBLASTOMA PATIENTS: THE CeTeg/NOA-09 trial. Neuro-Oncology, 2017, 19, vi13-vi14.	1.2	17
89	Unsupervised consensus cluster analysis of [18F]-fluoroethyl-L-tyrosine positron emission tomography identified textural features for the diagnosis of pseudoprogression in high-grade glioma. Oncotarget, 2017, 8, 8294-8304.	1.8	55
90	Dabrafenib in patients with recurrent, BRAF V600E mutated malignant glioma and leptomeningeal disease. Oncology Reports, 2017, 38, 3291-3296.	2.6	46

#	Article	IF	Citations
91	Endothelial cellâ€derived angiopoietinâ€2 is a therapeutic target in treatmentâ€naive and bevacizumabâ€resistant glioblastoma. EMBO Molecular Medicine, 2016, 8, 39-57.	6.9	140
92	Dynamic O-(2-[18F]fluoroethyl)-L-tyrosine PET imaging for the detection of checkpoint inhibitor-related pseudoprogression in melanoma brain metastases. Neuro-Oncology, 2016, 18, 1462-1464.	1.2	65
93	Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O⁶-Methylguanineâ€“DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial. Journal of Clinical Oncology, 2016, 34, 1611-1619.	1.6	151
94	Phase II Trial of Temsirolimus for Relapsed/Refractory Primary CNS Lymphoma. Journal of Clinical Oncology, 2016, 34, 1757-1763.	1.6	105
95	Complete resection of contrast-enhancing tumor volume is associated with improved survival in recurrent glioblastomaâ€”results from the DIRECTOR trial. Neuro-Oncology, 2016, 18, 549-556.	1.2	187
96	Late Pseudoprogression in Glioblastoma: Diagnostic Value of Dynamic O-(2-[18F]fluoroethyl)-L-Tyrosine PET. Clinical Cancer Research, 2016, 22, 2190-2196.	7.0	106
97	Gliomatosis cerebri: no evidence for a separate brain tumor entity. Acta Neuropathologica, 2016, 131, 309-319.	7.7	74
98	NIMG-40MRI TUMOR PROGRESSION PATTERNS IN THE GLARIUS TRIAL. Neuro-Oncology, 2015, 17, v162.4-v163.	1.2	0
99	NIMG-41MRI FINDINGS IN THE GLARIUS TRIAL: PROGNOSTIC AND PREDICTIVE IMPLICATIONS. Neuro-Oncology, 2015, 17, v163.1-v163.	1.2	0
100	Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology. Lancet Oncology, The, 2015, 16, e322-e332.	10.7	340
101	MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial. Clinical Cancer Research, 2015, 21, 2057-2064.	7.0	264
102	Randomized phase III study of whole-brain radiotherapy for primary CNS lymphoma. Neurology, 2015, 84, 1242-1248.	1.1	94
103	A single-arm phase II Austrian/German multicenter trial on continuous daily sunitinib in primary glioblastoma at first recurrence (SURGE 01-07). Neuro-Oncology, 2014, 16, 92-102.	1.2	57
104	Re-irradiation and bevacizumab in recurrent high-grade glioma: an effective treatment option. Journal of Neuro-Oncology, 2014, 117, 337-345.	2.9	66
105	Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncology, The, 2014, 15, 1100-1108.	10.7	800
106	MGMT promoter methylation as a prognostic biomarker for benefit from dose-intensified temozolomide rechallenge in progressive glioblastoma: First results from the randomized phase II DIRECTOR trial.. Journal of Clinical Oncology, 2014, 32, 2015-2015.	1.6	6
107	Survival and quality of life in the randomized, multicenter GLARIUS trial investigating bevacizumab/irinotecan versus standard temozolomide in newly diagnosed, MGMT-non-methylated glioblastoma patients.. Journal of Clinical Oncology, 2014, 32, 2042-2042.	1.6	11
108	Targeting the Cytosolic Innate Immune Receptors RIG-I and MDA5 Effectively Counteracts Cancer Cell Heterogeneity in Glioblastoma. Stem Cells, 2013, 31, 1064-1074.	3.2	76

#	Article	IF	Citations
109	Dose-intensified rechallenge with temozolomide: One week on/one week off versus 3 weeks on/one week off in patients with progressive or recurrent glioblastoma (DIRECTOR).. Journal of Clinical Oncology, 2013, 31, TPS2103-TPS2103.	1.6	0
110	Gliomatosis cerebri. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2012, 105, 507-515.	1.8	10
111	Late and Prolonged Pseudoprogression in Glioblastoma After Treatment With Lomustine and Temozolomide. Journal of Clinical Oncology, 2012, 30, e180-e183.	1.6	49
112	Primary CNS lymphoma in the elderly: temozolomide therapy and MGMT status. Journal of Neuro-Oncology, 2010, 97, 389-392.	2.9	72
113	Longâ€term survival with favorable cognitive outcome after chemotherapy in primary central nervous system lymphoma. Annals of Neurology, 2010, 67, 182-189.	5.3	108
114	Residual tumor cells are unique cellular targets in glioblastoma. Annals of Neurology, 2010, 68, 264-269.	5.3	105
115	High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. Lancet Oncology, The, 2010, 11, 1036-1047.	10.7	530
116	Should Intra-cerebrospinal Fluid Prophylaxis Be Part of Initial Therapy for Patients With Non-Hodgkin Lymphoma: What We Know, and How We Can Find Out More. Seminars in Oncology, 2009, 36, S25-S34.	2.2	19
117	Very late relapses in glioblastoma long-term survivors. Journal of Neurology, 2009, 256, 1756-1758.	3.6	25
118	Long-Term Survival of Patients With Glioblastoma Treated With Radiotherapy and Lomustine Plus Temozolomide. Journal of Clinical Oncology, 2009, 27, 1257-1261.	1.6	128
119	Vessel Wall Contrast Enhancement: A Diagnostic Sign of Cerebral Vasculitis. Cerebrovascular Diseases, 2008, 26, 23-29.	1.7	199
120	Efficacy and Tolerability of Temozolomide in an Alternating Weekly Regimen in Patients With Recurrent Glioma. Journal of Clinical Oncology, 2007, 25, 3357-3361.	1.6	237
121	Imaging-Guided Gene Therapy of Experimental Gliomas. Cancer Research, 2007, 67, 1706-1715.	0.9	62
122	Phase II Trial of Lomustine Plus Temozolomide Chemotherapy in Addition to Radiotherapy in Newly Diagnosed Glioblastoma: UKT-03. Journal of Clinical Oncology, 2006, 24, 4412-4417.	1.6	152
123	Relapse of primary central nervous system lymphoma: clinical features, outcome and prognostic factors. Journal of Neuro-Oncology, 2006, 80, 159-165.	2.9	171
124	Low-grade primary central nervous system lymphoma in immunocompetent patients. British Journal of Haematology, 2005, 128, 616-624.	2.5	53
125	NOA-03 trial of high-dose methotrexate in primary central nervous system lymphoma: Final report. Annals of Neurology, 2005, 57, 843-847.	5.3	181
126	UKT-04 trial of continuous metronomic low-dose chemotherapy with methotrexate and cyclophosphamide for recurrent glioblastoma. Journal of Neuro-Oncology, 2005, 71, 295-299.	2.9	35

#	Article	IF	Citations
127	Primary central nervous system lymphomas (PCNSL): MRI features at presentation in 100 patients. Journal of Neuro-Oncology, 2005, 72, 169-177.	2.9	335
128	Migratory neural stem cells for improved thymidine kinase-based gene therapy of malignant gliomas. Biochemical and Biophysical Research Communications, 2005, 328, 125-129.	2.1	54
129	Diffusion Abnormality in Baloâ€™s Concentric Sclerosis: Clues for the Pathogenesis. European Neurology, 2005, 53, 42-44.	1.4	26
130	SD-208, a Novel Transforming Growth Factor Î² Receptor I Kinase Inhibitor, Inhibits Growth and Invasiveness and Enhances Immunogenicity of Murine and Human Glioma Cells In vitro and In vivo. Cancer Research, 2004, 64, 7954-7961.	0.9	380
131	MIP-1Â Antagonizes the Effect of a GM-CSF-Enhanced Subcutaneous Vaccine in a Mouse Glioma Model. Journal of Neuro-Oncology, 2004, 66, 147-154.	2.9	13
132	Leptomeningeal metastasis: survival and prognostic factors in 155 patients. Journal of the Neurological Sciences, 2004, 223, 167-178.	0.6	150
133	German Cancer Society Neuro-Oncology Working Group NOA-03 multicenter trial of single-agent high-dose methotrexate for primary central nervous system lymphoma. Annals of Neurology, 2002, 51, 247-252.	5.3	161
134	Gliomatosis cerebri: Molecular pathology and clinical course. Annals of Neurology, 2002, 52, 390-399.	5.3	83
135	Primary central nervous system lymphoma 1991-1997. Cancer, 2001, 91, 130-135.	4.1	46
136	HSV-1 infected cell proteins influence tetracycline-regulated transgene expression. Journal of Gene Medicine, 2000, 2, 379-389.	2.8	20
137	Treosulfan chemotherapy for recurrent malignant glioma. Journal of Neuro-Oncology, 2000, 49, 231-234.	2.9	10
138	Neural Precursor Cells for Delivery of Replication-Conditional HSV-1 Vectors to Intracerebral Gliomas. Molecular Therapy, 2000, 1, 347-357.	8.2	151
139	Intraarterial Delivery of Adenovirus Vectors and Liposome-DNA Complexes to Experimental Brain Neoplasms. Human Gene Therapy, 1999, 10, 311-318.	2.7	51
140	Primary CNS lymphoma: findings outside the brain. , 1999, 43, 227-230.		45
141	Primary central nervous system lymphoma: from clinical presentation to diagnosis. Journal of Neuro-Oncology, 1999, 43, 219-226.	2.9	84
142	Intrathecal therapy of leptomeningeal CEM T-cell lymphoma in nude rats with anti-CD7 ricin toxin A chain immunotoxin. Journal of Neuro-Oncology, 1998, 40, 1-9.	2.9	5
143	New aspects of immunotherapy of leptomeningeal metastasis. Journal of Neuro-Oncology, 1998, 38, 233-239.	2.9	39
144	Targeting gene therapy vectors to CNS malignancies. Journal of NeuroVirology, 1998, 4, 133-147.	2.1	23

#	Article	IF	Citations
145	New Prodrug Activation Gene Therapy for Cancer Using Cytochrome P450 4B1 and 2-Aminoanthracene/4-Ipomeanol. Human Gene Therapy, 1998, 9, 1261-1273.	2.7	69
146	Intrathecal treatment of C6 glioma leptomeningeal metastasis in Wistar rats with interlenkin-2. Journal of Neuro-Oncology, 1996, 27, 193-203.	2.9	11
147	Long-Term Survival in a Rodent Model of Disseminated Brain Tumors by Combined Intrathecal Delivery of Herpes Vectors and Ganciclovir Treatment. Human Gene Therapy, 1996, 7, 1989-1994.	2.7	66
148	Prognostic impact of obesity in newly-diagnosed glioblastoma: a secondary analysis of CeTeG/NOA-09 and GLARIUS. Journal of Neuro-Oncology, 0, , .	2.9	1